# US 8,278,406 B2 · Bioactive and biocompatible polyurethane-buthanediol-glycosaminoglycan salt copolymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,406 B2
- Document ID: US8278406B2
- Status: Granted
- Kind: B2
- Application number: 12/110,096
- Filed: 2008-04-25
- Published: 2008-11-27
- Granted: 2012-10-02
- Earliest claimed: 2007-04-27
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Kristyn S. Masters; Wendy C. Crone; Fangmin Xu
- Web page: https://patentgrep.com/patent/US8278406B2

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/75: of ethene
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 33/0035: {using a polymer with positively charged atoms in the polymeric backbone, e.g. ionenes}
- C08B 37/0063: {Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan}
- C08B 37/0069: {Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof}
- C08B 37/0072: {Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates}
- C08B 37/0075: {Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof}
- C08G 18/10: Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
- C08G 18/4854: {Polyethers containing oxyalkylene groups having four carbon atoms in the alkylene group}
- C08G 18/6484: {Polysaccharides and derivatives thereof}
- C08G 18/7657: {containing two or more aromatic rings}
- C08G 18/7671: {containing only one alkylene bisphenyl group}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS

## Abstract

A bioactive and biocompatible polyurethane-butanediol-glycosaminoglycan copolymer for use in medical implant devices. The biocompatible urethane component being the reaction product of 4,4′-methylene-di-(p-phenyl isocyanate) and poly(tetramethylene oxide)n and further reacted with 1,4-butanediol, wherein n=10 to 40. The bioactive glycosaminoglycan being a salt of hyaluronic acid, such as a cetylpyridinium salt acid having 5 to 10,000 repeating units or a salt of heparin, such as a dimethyldioctadecylammonium salt of heparin has 5 to 65 repeating units or a suitable salt of dermatan sulfate. The weight content of the bioactive glycosaminoglycan is an amount sufficient to render the copolymer bioactive. The copolymers described herein have excellent hemocompatibility and biocompatibility.

## Claims

### Claim 1

A copolymer comprising the polymerization reaction product of a biocompatible polyurethane and a bioactive polysaccharide, wherein the bioactive polysaccharide is incorporated into the polyurethane backbone of the copolymer.

### Claim 2 (depends on 1)

The copolymer of claim 1, wherein the bioactive polysaccharide is a bioactive glycosaminoglycan.

### Claim 3 (depends on 2)

The copolymer of claim 2, wherein the bioactive glycosaminoglycan is a member selected from the group consisting of a suitable salt of hyaluronic acid, a suitable salt of heparin, and a suitable salt of dermatan sulfate.

### Claim 4 (depends on 3)

The copolymer of claim 3, wherein the salt of hyaluronic acid is a member selected from the group consisting of a cetylpyridinium salt and a tetrabutylammonium salt, and wherein the salt of heparin is a dimethyldioctadecylammorium salt.

### Claim 5 (depends on 4)

The copolymer of claim 4, wherein the salt of hyaluronic acid has 5 to 10,000 repeating units, and wherein the dimethyldioctadecylammonium salt of heparin has 5 to 65 repeating units.

### Claim 6 (depends on 1)

The copolymer of claim 1, wherein the weight content of the bioactive polysaccharide is in the range of about 0.05% to about 30%.

### Claim 7 (depends on 6)

The copolymer of claim 6, wherein the high and low range endpoints of the weight content of the bioactive polysaccharide are any combination of members selected from the group consisting of 0.05%, 0.1%, 0.33%, 0.66%, 1.3%, 2.0%, 5.4%, 10%, 20% and 30%.

### Claim 8 (depends on 7)

The copolymer of claim 7, comprising the cetylpyridinium salt of hyaluronic acid.

### Claim 9 (depends on 7)

The copolymer of claim 7, wherein the biocompatible polyurethane is the reaction product of 4,4′-methylene-di-(p-phenyl isocyanate) and poly(tetramethylene oxide)n and further reacted with 1,4-butanediol, and wherein n=10 to 40.

### Claim 10 (depends on 8)

The copolymer of claim 8, wherein the biocompatible polyurethane is the reaction product of 4,4′-methylene-di-(p-phenyl isocyanate) and poly(tetramethylene oxide)n and further reacted with 1,4-butanediol, and wherein n=10 to 40.

### Claim 11 (depends on 6)

The copolymer of claim 6, wherein the biocompatible polyurethane is the reaction product of a suitable isocyanate-containing molecule and a suitable poly(C2-10 alkylene oxide)n and further reacted with a suitable C4-50 diol-containing molecule, wherein n=10 to 40, wherein the C2-10 alkylene is linear or branched, substituted or un-substituted, and wherein the C4-50 is linear or branched, substituted or un-substituted.

### Claim 12

A method of making a bioactive and biocompatible polyurethane-diol-polysaccharide copolymer comprising:
reacting a suitable isocyanate-containing molecule and a suitable poly(C2-10 alkylene oxide)n to produce a diisocyanate reactant, and, reacting the diisocyanate reactant with a suitable C4-50 diol-containing molecule and a bioactive polysaccharide,
wherein n=10 to 40,
wherein the C2-10 alkylene is linear or branched, substituted or un-substituted, and,
wherein the C4-50 is linear or branched, substituted or un-substituted.

### Claim 13 (depends on 12)

The method of claim 12, wherein the bioactive polysaccharide is a bioactive glycosaminoglycan.

### Claim 14 (depends on 13)

The method of claim 13, wherein the glycosaminoglycan is a member selected from the group consisting of a suitable salt of hyaluronic acid, a suitable salt of heparin, and a suitable salt of dermatan sulfate.

### Claim 15 (depends on 14)

The method of claim 14, wherein the salt of hyaluronic acid is a member selected from the group consisting of a cetylpyridinium salt and a tetrabutylammonium salt, and wherein the salt of heparin is a dimethyldioctadecylammonium salt.

### Claim 16 (depends on 15)

The method of claim 15, wherein the salt of hyaluronic acid has 5 to 10,000 repeating units, and wherein the dimethyldioctadecylammonium salt of heparin has 5 to 65 repeating units.

### Claim 17 (depends on 12)

The method of claim 12, wherein the weight content of the bioactive polysaccharide is in the range of about 0.05% to about 30%.

### Claim 18 (depends on 17)

The method of claim 17, wherein the high and low range endpoints of the weight content of the bioactive polysaccharide are any combination of members selected from the group consisting of 0.05%, 0.1%, 0.33%, 0.66%, 1.3%, 2.0%, 5.4%, 10%, 20% and 30%.

### Claim 19

A method of making a bioactive and biocompatible polyurethane-butanediol-glycosaminoglycan salt copolymer comprising:
reacting 4,4′-methylene-di-(p-phenyl isocyanate) and poly(tetramethylene oxide)n to produce a diisocyanate reactant, and,
reacting the diisocyanate reactant with 1,4-butanediol and a bioactive glycosaminoglycan salt selected from the group consisting of a suitable salt of hyaluronic acid and a suitable salt of heparin,
wherein n=10 to 40.

### Claim 20 (depends on 19)

The method of claim 19, wherein the salt of hyaluronic acid is a member selected from the group consisting of a cetylpyridinium salt and a tetrabutylammonium salt, and wherein the salt of heparin is a dimethyldioctadecylammonium salt.

### Claim 21 (depends on 20)

The method of claim 20, wherein the salt of hyaluronic acid has 5 to 10,000 repeating units, and wherein the dimethyldioctadecylammonium salt of heparin has 5 to 65 repeating units.

### Claim 22 (depends on 21)

The method of claim 21, comprising the cetylpyridinium salt of hyaluronic acid having 5 to 10,000 repeating units.

### Claim 23 (depends on 19)

The method of claim 19, wherein the weight content of the bioactive glycosaminoglycan salt is in the range of about 0.05% to about 30%.

### Claim 24 (depends on 23)

The method of claim 23, wherein the high and low range endpoints of the weight content of the bioactive glycosaminoglycan salt are any combination of members selected from the group consisting of 0.05%, 0.1%, 0.33%, 0.66%, 1.3%, 2.0%, 5.4%, 10%, 20% and 30%.
